^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Published date:
09/14/2020
Excerpt:
In Pembro cohort, median overall survival in low and high sPD-L1 level groups were 16.0 and 10.9 months, respectively (p=0.045). No difference in progression-free survival or objective response was observed...baseline sPD-L1 is associated with poor prognosis in advanced NSCLC patients treated with Pembro in first line.
